Medical device company Varian Medical Systems (NYSE:VAR) disclosed on Monday the launch of its new FDA 510(k) cleared cancer-fighting treatment planning system, Eclipse 15.5, which will provide clinicians with powerful new tools to quickly create optimised treatment plans that are unique to each patient.

The company said Eclipse 15.5 incorporates several new treatment capabilities that offer clinicians the ability to create more precise treatment plans quickly as well as provides treatment planning support for its HyperArc HDRT, a new type of radiosurgery treatment.

According to the company, Eclipse 15.5 features MCO, which allows clinicians to explore what happens when different clinical criteria are varied, as well as leverages both RapidPlan and the existing optimization workflows to expedite finding the optimal plan for a given patient with minimal trial and error iterations.

For efficient treatment planning and automated delivery of complex stereotactic radiosurgery, Eclipse 15.5 now supports HyperArc treatments, which exploit specific capabilities of the platforms to deliver more compact radiation doses that can fully saturate a targeted tumor and "fall off" sharply outside the target zone, minimizing and, where necessary, even eliminating dose to specific organs requiring more protection, added the company.

In conjunction, Eclipse 15.5 offers Graphics Processing Unit (GPU) support to increase the speed of plan development as well as enables clinicians to utilise GPU technology to optimize and calculate the dose with Eclipse and the intermediate dose calculation, concluded the company.